NL8503097A - Geneesmiddel met thrombolytische werking. - Google Patents
Geneesmiddel met thrombolytische werking. Download PDFInfo
- Publication number
- NL8503097A NL8503097A NL8503097A NL8503097A NL8503097A NL 8503097 A NL8503097 A NL 8503097A NL 8503097 A NL8503097 A NL 8503097A NL 8503097 A NL8503097 A NL 8503097A NL 8503097 A NL8503097 A NL 8503097A
- Authority
- NL
- Netherlands
- Prior art keywords
- urokinase
- plasminogen activator
- type
- medicament
- combination
- Prior art date
Links
- 230000002537 thrombolytic effect Effects 0.000 title claims description 21
- 229940126601 medicinal product Drugs 0.000 title claims description 3
- 102000001938 Plasminogen Activators Human genes 0.000 claims abstract description 23
- 108010001014 Plasminogen Activators Proteins 0.000 claims abstract description 23
- 229940127126 plasminogen activator Drugs 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 8
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 22
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 22
- 229960005356 urokinase Drugs 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 6
- 238000001802 infusion Methods 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 3
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 3
- 239000003146 anticoagulant agent Substances 0.000 claims description 3
- 239000003978 infusion fluid Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 208000005189 Embolism Diseases 0.000 claims 2
- 208000001435 Thromboembolism Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003527 fibrinolytic agent Substances 0.000 abstract description 7
- 230000002195 synergetic effect Effects 0.000 abstract description 6
- 238000001727 in vivo Methods 0.000 abstract description 4
- 229960000103 thrombolytic agent Drugs 0.000 abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 208000007536 Thrombosis Diseases 0.000 description 9
- 230000004913 activation Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 102000009123 Fibrin Human genes 0.000 description 5
- 108010073385 Fibrin Proteins 0.000 description 5
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 5
- 108010049003 Fibrinogen Proteins 0.000 description 5
- 102000008946 Fibrinogen Human genes 0.000 description 5
- 229950003499 fibrin Drugs 0.000 description 5
- 229940012952 fibrinogen Drugs 0.000 description 5
- 102000013566 Plasminogen Human genes 0.000 description 4
- 108010051456 Plasminogen Proteins 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000003636 conditioned culture medium Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000003480 fibrinolytic effect Effects 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940106780 human fibrinogen Drugs 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000033885 plasminogen activation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (18)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL8503097A NL8503097A (nl) | 1985-11-11 | 1985-11-11 | Geneesmiddel met thrombolytische werking. |
| ZA868464A ZA868464B (en) | 1985-11-11 | 1986-11-06 | Pharmaceutical composition having thrombolytic activity |
| DK532886A DK164640C (da) | 1985-11-11 | 1986-11-07 | Farmaceutisk praeparat med thrombolytisk aktivitet og fremgangsmaade til fremstilling deraf |
| IL80538A IL80538A (en) | 1985-11-11 | 1986-11-07 | Pharmaceutical composition having thrombolytic activity |
| AU65031/86A AU586713B2 (en) | 1985-11-11 | 1986-11-10 | Pharmaceutical composition having thrombolytic activity |
| PH34452A PH23192A (en) | 1985-11-11 | 1986-11-10 | Pharmaceutical compositions having thrombolytic activity |
| CA000522568A CA1303987C (en) | 1985-11-11 | 1986-11-10 | Pharmaceutical composition having thrombolytic activity |
| IE296286A IE59387B1 (en) | 1985-11-11 | 1986-11-10 | Pharmaceutical composition having thrombolytic activity |
| NZ218231A NZ218231A (en) | 1985-11-11 | 1986-11-10 | Composition containing synergistic combination of plasminogen activator and urokinase activator |
| PT83721A PT83721B (pt) | 1985-11-11 | 1986-11-11 | Processo de preparacao de composicoes farmaceuticas a base de activadores de plasminogenio com actividade trombolitica |
| ES198686115665T ES2039194T3 (es) | 1985-11-11 | 1986-11-11 | Un metodo de preparar una composicion farmaceutica tromboliticamente activa. |
| DE8686115665T DE3679887D1 (de) | 1985-11-11 | 1986-11-11 | Pharmazeutische zusammensetzung mit thrombolytischer wirkung. |
| JP61269506A JPH089546B2 (ja) | 1985-11-11 | 1986-11-11 | 抗血栓医薬組成物 |
| AT86115665T ATE64532T1 (de) | 1985-11-11 | 1986-11-11 | Pharmazeutische zusammensetzung mit thrombolytischer wirkung. |
| HU864649A HU196715B (en) | 1985-11-11 | 1986-11-11 | Process for producing pharmaceutical compositions with thrombolytic effect |
| EP86115665A EP0223192B1 (en) | 1985-11-11 | 1986-11-11 | Pharmaceutical composition having thrombolytic activity |
| US07/384,117 US5174994A (en) | 1985-11-11 | 1989-07-21 | Pharmaceutical composition having thrombolytic activity |
| GR91400921T GR3002226T3 (en) | 1985-11-11 | 1991-07-02 | Pharmaceutical composition having thrombolytic activity |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL8503097A NL8503097A (nl) | 1985-11-11 | 1985-11-11 | Geneesmiddel met thrombolytische werking. |
| NL8503097 | 1985-11-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8503097A true NL8503097A (nl) | 1987-06-01 |
Family
ID=19846844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8503097A NL8503097A (nl) | 1985-11-11 | 1985-11-11 | Geneesmiddel met thrombolytische werking. |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0223192B1 (da) |
| JP (1) | JPH089546B2 (da) |
| AT (1) | ATE64532T1 (da) |
| AU (1) | AU586713B2 (da) |
| CA (1) | CA1303987C (da) |
| DE (1) | DE3679887D1 (da) |
| DK (1) | DK164640C (da) |
| ES (1) | ES2039194T3 (da) |
| GR (1) | GR3002226T3 (da) |
| HU (1) | HU196715B (da) |
| IE (1) | IE59387B1 (da) |
| IL (1) | IL80538A (da) |
| NL (1) | NL8503097A (da) |
| NZ (1) | NZ218231A (da) |
| PH (1) | PH23192A (da) |
| PT (1) | PT83721B (da) |
| ZA (1) | ZA868464B (da) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8623823D0 (en) * | 1986-10-03 | 1986-11-05 | Sandoz Ltd | Therapeutic lysis of fibrin blood clots |
| SE462829B (sv) * | 1989-01-10 | 1990-09-10 | Kabigen Ab | Trombolytiskt aktiva kompositioner innehaallande en modifierad plasminogenaktivator av vaevnadstyp samt en normal human t-pa, streptokinas eller humant urokinas |
| ATE135200T1 (de) * | 1989-05-17 | 1996-03-15 | Res Corp Technologies Inc | Verfahren und zusammensetzung zur thrombosebehandlung beim säugetier |
| GB8919803D0 (en) * | 1989-09-01 | 1989-10-18 | Ciba Geigy | Pharmaceutical compositions |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1642612A1 (de) * | 1967-03-02 | 1971-09-09 | Bayer Ag | Die Verwendung von Erythrozyten zur Gewinnung bzw.Isolierung eines Plasminogen-Aktivators |
| NL8003402A (nl) * | 1980-06-11 | 1982-01-04 | Leuven Res & Dev Vzw | Nieuwe plasminogeen-activator en farmaceutisch preparaat met trombolytische werking. |
| ZA833174B (en) * | 1982-05-05 | 1984-08-29 | Genentech Inc | Human tissue plasminogen activator |
| JPS5951220A (ja) * | 1982-08-02 | 1984-03-24 | Asahi Chem Ind Co Ltd | 新規なプラスミノ−ゲン・アクチベ−タ−およびその製法ならびにこれを含有する薬剤 |
| JPH0637398B2 (ja) * | 1982-10-29 | 1994-05-18 | 三井東圧化学株式会社 | 血栓溶解剤 |
| JPS59139323A (ja) * | 1983-01-28 | 1984-08-10 | Green Cross Corp:The | ウロキナ−ゼ乾燥製剤 |
| JPS6051119A (ja) * | 1983-08-30 | 1985-03-22 | Green Cross Corp:The | ウロキナ−ゼ乾燥製剤 |
| JPS60152421A (ja) * | 1984-01-23 | 1985-08-10 | Sanwa Kagaku Kenkyusho:Kk | ヒト胎盤性プラスミノ−ゲン活性化因子、及びそれとヒトプラスミノ−ゲン活性化阻害因子との結合物、及びそれらの製法 |
| GB8430253D0 (en) * | 1984-11-30 | 1985-01-09 | Beecham Group Plc | Compounds |
| ATE142502T1 (de) * | 1986-05-15 | 1996-09-15 | Univ Emory | Injizierbares arzneimittel zum schutz vor gewebebeschädigung durch ischemie |
| NL8702234A (nl) * | 1986-10-03 | 1988-05-02 | Sandoz Ag | Verbeteringen aan of met betrekking tot organische verbindingen. |
-
1985
- 1985-11-11 NL NL8503097A patent/NL8503097A/nl not_active Application Discontinuation
-
1986
- 1986-11-06 ZA ZA868464A patent/ZA868464B/xx unknown
- 1986-11-07 IL IL80538A patent/IL80538A/xx unknown
- 1986-11-07 DK DK532886A patent/DK164640C/da not_active IP Right Cessation
- 1986-11-10 IE IE296286A patent/IE59387B1/en not_active IP Right Cessation
- 1986-11-10 AU AU65031/86A patent/AU586713B2/en not_active Ceased
- 1986-11-10 NZ NZ218231A patent/NZ218231A/xx unknown
- 1986-11-10 PH PH34452A patent/PH23192A/en unknown
- 1986-11-10 CA CA000522568A patent/CA1303987C/en not_active Expired - Lifetime
- 1986-11-11 EP EP86115665A patent/EP0223192B1/en not_active Expired - Lifetime
- 1986-11-11 AT AT86115665T patent/ATE64532T1/de not_active IP Right Cessation
- 1986-11-11 DE DE8686115665T patent/DE3679887D1/de not_active Expired - Lifetime
- 1986-11-11 PT PT83721A patent/PT83721B/pt not_active IP Right Cessation
- 1986-11-11 ES ES198686115665T patent/ES2039194T3/es not_active Expired - Lifetime
- 1986-11-11 HU HU864649A patent/HU196715B/hu not_active IP Right Cessation
- 1986-11-11 JP JP61269506A patent/JPH089546B2/ja not_active Expired - Lifetime
-
1991
- 1991-07-02 GR GR91400921T patent/GR3002226T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL80538A0 (en) | 1987-02-27 |
| PT83721A (en) | 1986-12-01 |
| IE59387B1 (en) | 1994-02-23 |
| JPS62155222A (ja) | 1987-07-10 |
| AU586713B2 (en) | 1989-07-20 |
| IL80538A (en) | 1991-06-30 |
| CA1303987C (en) | 1992-06-23 |
| DE3679887D1 (de) | 1991-07-25 |
| ATE64532T1 (de) | 1991-07-15 |
| HUT43794A (en) | 1987-12-28 |
| HU196715B (en) | 1989-01-30 |
| ES2039194T3 (es) | 1993-09-16 |
| DK532886A (da) | 1987-05-12 |
| JPH089546B2 (ja) | 1996-01-31 |
| PT83721B (pt) | 1988-08-17 |
| DK532886D0 (da) | 1986-11-07 |
| DK164640C (da) | 1992-12-14 |
| NZ218231A (en) | 1988-10-28 |
| EP0223192B1 (en) | 1991-06-19 |
| PH23192A (en) | 1989-05-29 |
| ZA868464B (en) | 1987-06-24 |
| AU6503186A (en) | 1987-05-14 |
| EP0223192A1 (en) | 1987-05-27 |
| GR3002226T3 (en) | 1992-12-30 |
| DK164640B (da) | 1992-07-27 |
| IE862962L (en) | 1987-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2766986B2 (ja) | 動脈の血栓症的閉塞または塞栓症を阻止するための医薬組成物 | |
| Goldhaber et al. | Acute pulmonary embolism treated with tissue plasminogen activator | |
| Collen et al. | Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells. | |
| Gold et al. | Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion. | |
| Van de Werf et al. | Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction. | |
| EP0196920B1 (en) | Degraded species of tissue-type plasminogen activator, pharmaceutical composition and method of preparation | |
| Been et al. | Clinical effects and kinetic properties of intravenous APSAC—anisoylated plasminogen-streptokinase activator complex (BRL 26921) in acute myocardial infarction | |
| Ambrus et al. | On the mechanism of thrombolysis by plasmin | |
| Bode et al. | Efficacy of intravenous prourokinase and a combination of prourokinase and urokinase in acute myocardial infarction | |
| NL8200004A (nl) | Gestabiliseerde plasmine samenstellingen en werkwijze voor de bereiding ervan. | |
| Gurewich | Experiences with pro-urokinase and potentiation of its fibrinolytic effect by urokinase and by tissue plasminogen activator | |
| Marder | Relevance of changes in blood fibrinolytic and coagulation parameters during thrombolytic therapy | |
| Topol et al. | Thrombolysis with recombinant tissue plasminogen activator in atherosclerotic thrombotic occlusion | |
| Gans | Thrombogenic properties of epsilon amino caproic acid | |
| Collen et al. | Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model | |
| CA1303987C (en) | Pharmaceutical composition having thrombolytic activity | |
| US5583113A (en) | Use of a direct-acting thrombin inhibitor for the manufacture of a medicinal product having thrombolytic activity | |
| EP0099126B1 (en) | Thrombolytic composition | |
| Bergstein et al. | Tissue plasminogen activator therapy of glomerular thrombi in the Shwartzman reaction | |
| Leaker et al. | Fibrin clot lysis by tissue plasminogen activator (tPA) is impaired in plasma from pediatric patients undergoing orthotopic liver transplantation | |
| Pilger et al. | Intraarterial fibrinolysis: in vitro and prospective clinical evaluation of three thrombolytic agents. | |
| US5174994A (en) | Pharmaceutical composition having thrombolytic activity | |
| Badylak et al. | The beneficial effect of lys-plasminogen upon the thrombolytic efficacy of urokinase in a dog model of peripheral arterial thrombosis | |
| EP0381640B1 (en) | New thrombolytic compositions | |
| Roschlau et al. | Human fibrinolysin with and without urokinase: its effect on experimental arterial thrombi in dogs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1B | A search report has been drawn up | ||
| BV | The patent application has lapsed |